Chemotherapy-induced peripheral neuropathy (CIPN) is a complication caused by several anti-cancer drugs, which profoundly affects the patient's quality of life. Paclitaxel (PTX) is used in the treatment of common cancers, and usually causes dysesthesias, paresthesias and numbness, hypersensitivity to mechanical stimuli, that patients frequently suffer in feet and hands. Mirogabalin (MGB) has been developed as a novel gabapentinoid, and its analgesic effect is exerted by binding to the α₂δ-1 subunit of voltage-gated calcium channels. Although MGB is used for the treatment of peripheral neuropathic pain including diabetic peripheral neuropathy and postherpetic neuralgia, no clinical studies have been reported in CIPN. Here, we conducted an investigate the effects of MGB on PTX-induced peripheral neuropathic pain. A single oral administration of MGB dose-dependently inhibited PTX-induced mechanical allodynia but did not affect locomotor activity. Next, we administered MGB topically and found that intrathecal injection suppressed mechanical allodynia, but intradermal injection into footpad did not. In fact, α₂δ-1 protein expression was increased in the spinal cord on the PTX model. Together, these results suggest MGB inhibits PTX-induced mechanical allodynia by acting on α₂δ-1 subunit in the spinal dorsal horn.